Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Latest Content

Akari enrols seven out of nine patients in bullous pemphigoid trial

Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has so far enrolled seven out of its nine-patient target as of three to four weeks ago, a source with knowledge of the trial said. The trial was aimed to complete within six months but it is still enrolling in its eighth month, the source noted, adding it is hoped the final two patients would be recruited in the next couple of months.

Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane

While Cassiopea’s Winlevi (clascoterone) is likely to be FDA approved in moderate-to-severe acne, it is at risk of diminishing clinician/patient interest following initially optimistic early uptake, experts said. The market wane could happen if clinical trial data does not match real-world experience, even if early adoption would be driven by its novel antiandrogen mechanism, they said.

Related Treatments


Go Top